The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

Published:2021-01 Issue:1 Volume:2 Page:100186
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Salgia Ravi^ORCID,Pharaon Rebecca^ORCID,Mambetsariev Isa^ORCID,Nam Arin,Sattler Martin

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference132 articles.

1. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC;Awad;J. Thorac. Oncol.,2020

2. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure;Barbie;Clin. Lung Cancer,2018

3. A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER;Goldman;J. Clin. Oncol.,2018

4. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells;Takezawa;Cancer Res.,2009

5. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations;Riely;J. Clin. Oncol.,2012

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. METTL3 -mediated m6A modification of circ_0000620 regulates cisplatin sensitivity and apoptosis in lung adenocarcinoma via the MiR-216b-5p/KRAS axis;Cellular Signalling;2024-11

2. SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers;Nature Communications;2024-09-12

3. Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer;Frontiers in Immunology;2024-08-23

4. Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells;Cancers;2024-07-20

5. Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer;Human Genetics and Genomics Advances;2024-07